Upadacitinib Tablets Suppliers & Bulk Manufacturers

Available Forms: Tablets

Available Strengths: 15 mg, 30 mg

Reference Brands: Rinvoq(US & EU)

Category: Arthritis

Upadacitinib inhibits Janus kinase (JAK) enzymes, blocking cytokine signaling involved in inflammation. It effectively reduces symptoms and disease progression in rheumatoid arthritis. Benefits include rapid relief, improved joint function, and better quality of life, with convenient oral dosing and a safety profile suitable for long-term autoimmune therapy when monitored properly. Upadacitinib tablets is available in Tablets and strengths such as 15 mg, 30 mg. Sourced from GMP-certified and ISO-compliant manufacturers, this API meets global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical formulation and commercial manufacturing, Upadacitinib tablets is supplied in bulk quantities with complete regulatory support including DMF, COA, and MSDS.

Upadacitinib tablets can be exported to over 30 countries across Asia, Africa, Europe, and Latin America. Flexible packaging, competitive pricing, and a verified supplier network make Pharmatradz a trusted sourcing partner for pharmaceutical companies and contract manufacturers worldwide.

Product Description: Upadacitinib tablets are approved in the EU and US for moderate to severe rheumatoid arthritis. In the EU, AbbVie’s Rinvoq is regulated by EMA, supported by dossiers demonstrating safety, efficacy, and quality manufacturing. In the US, FDA approval is based on extensive clinical trial data, biosimilarity, and pharmacovigilance. Both regions require detailed dossiers for initial approval and ongoing safety monitoring. For expert assistance with regulatory dossiers, compliance, and registration, visit PharmaTradz. We support efficient market access for upadacitinib tablets, ensuring adherence to European and American standards for safe, effective autoimmune disease management, helping you navigate complex regulatory processes seamlessly.